职称：副教授

      邮箱：shixiaojing@zzu.edu.cn

      地址：郑州大学医学科学院

个人简介：

2023/03 - 至今，郑州大学，医学科学院，副教授

2021/06 - 至今，郑州大学，实验动物中心，科研教学部，科长

2018/06 - 2023/11，郑州大学，化学学院，博士后

2020/02 - 2023/03，郑州大学，医学科学院，讲师

2017/09 - 2020/02，郑州大学，药学院，讲师

2011/09 - 2017/06，郑州大学，药学院药物化学系，博士

2007/09 - 2011/06，青海大学，医学院药学系，学士

主要研究方向

基于泛素化与表观遗传相关靶点小分子抑制剂的开发，难治性消化道肿瘤发病机制的探究，消化道肿瘤PDX模型库及人源化小鼠等各种人类疾病动物模型的研发。

荣誉及获奖情况

1)2018，第11届世界华人药物化学研讨会墙报奖

2)2016，郑州大学优秀科研成果奖

3)2016，国际心脏研究会中国分会第十三届、中国病理生理学会心血管专业委员会第十六届学术大会优秀论文Poster奖

主持或参加科研项目情况

1.国家自然科学基金青年项目，82103996，2022.01-2024.12, 30万

2.河南省自然科学基金青年项目，212300410253，2021.01-2022.12，5万元

3.河南省高等学校重点科研项目基础研究计划，19A350012，2019.01-2020.12，3万元

4.科技部政府间国际科技创新合作重点专项，2018YFE0195100，2020.01-2022.12，276万

代表性成果

（#共同第一作者，*通讯作者）

1.Binglei Zhang^#, Jianxiang Shi^#, Xiaojing Shi^#, Xiaolu Xu, Le Gao, Song Li, Mengmeng Liu, Mengya Gao, Shuiling Jin, Jian Zhou, Dandan Fan, Fang Wang, Zhenyu Ji, Zhilei Bian, Yongping Song, Wenzhi Tian, Yichao Zheng*, Linping Xu*, Wei Li*. Development and evaluation of a human CD47/HER2 bispecific antibody for Trastuzumab-resistant breast cancer immunotherapy. Drug Resistance Updates. 2024,74:101068.

2.Hui-Hui Hu ^#, Sai-Qi Wang^#, Huichen Zhao, Zhe-Sheng Chen, Xiaojing Shi*, Xiao-Bing Chen*. HER2+ advanced gastric cancer: Current state and opportunities (Review). International Journal of Oncology. 2024, 64(4): 36.

3.Yecheng Feng, Wenjing Yang, Xiaojing Shi*, Xubo Zhao*. ZnO-incorporated alginate assemblies: Tunable pH-responsiveness and improved drug delivery for cancer therapy. International Journal of Biological Macromolecules. 2024, 255, 128189.

4.Moges Dessale Asmamaw, Li-Rong Zhang, Hong-Min Liu, Xiao-Jing Shi*, Ying Liu*. Skp2 is a novel regulator of LSD1 expression and function in gastric cancer. Genes & Diseases. 2023,10,2267-2269.

5.Mingbo Cai ^#, Sulong Xu^#, Yuxi Jin, Jingjing Yu, Shan Dai, Xiao-Jing Shi*, Ruixia Guo*. hMOF induces cisplatin resistance of ovarian cancer by regulating the stability and expression of MDM2. Cell Death Discovery. 2023, 9(1):179.

6.Kun Zhang^#, Kaizhao Hu^#, Qian Li, Min Li, Ke Gao, Kecheng Yang, Bing Zhao*, Xiao-Jing Shi*, Lirong Zhang*, Hong-Min Liu*. Discovery of Novel 1,3-Diphenylpyrazine Derivatives as Potent SPhase Kinase-Associated Protein 2 (Skp2) Inhibitors for the. Journal of Medicinal Chemistry. 2023,66,7221-7242.

7.Zan Song, Ke Gao, Moges Dessale Asmamaw, Yue-Jiao Liu, Yi-Chao Zheng, Xiao-Jing Shi*, Hong-Min Liu*. Discovery of the antitumor activities of a potent DCN1 inhibitor compound 383 targeting LSD1 in gastric cancer. European Journal of Pharmacology. 2022, 916: 174725.

8.Kaizhao Hu, Xiao-Jing Li, Moges Dessale Asmamaw, Xiao-Jing Shi*, Hong-Min Liu*. Establishment of high-throughput screening HTRF assay for identification small molecule inhibitors of Skp2-Cks1. Scientific Reports. 2021, 11(1): 21105.

9.Kunlun Chen^#, Pengfei Zhu^#, Wenhui Chen, Kai Luo, Xiao-Jing Shi*, Wenlong Zhai*. Melatonin inhibits proliferation, migration, and invasion by inducing ROS-mediated apoptosis via suppression of the PI3K/Akt/mTOR signaling pathway in gallbladder cancer cells. Aging-US. 2021, 13: 22502-22515.9

10.Ke Yan, Yecheng Feng, Ke Gao, Xiaojing Shi*, Xubo Zhao*. Fabrication of hyaluronic acid-based micelles with glutathione-responsiveness for targeted anticancer drug delivery. Journal of Colloid and Interface Science. Journal of Colloid and Interface Science. 2022, 606(2), 1586-1596.

11.Yudian Qiu, Jie Bai, Yecheng Feng, Xiaojing Shi*, Xubo Zhao*. Use of pH-Active Catechol-Bearing Polymeric Nanogels with Glutathione-Responsive Dissociation to Codeliver Bortezomib and Doxorubicin for the Synergistic Therapy of Cancer. ACS Applied Materials & Interfaces. 2021, 13(31): 36926-36937.

12.Xiao-Jing Shi^#, Shuai Wang^#, Xiao-Jing Li^#, Xiao-Han Yuan, Li-Juan Cao, Bin Yu*, Hongmin Liu*. Discovery of tofacitinib derivatives as orally active antitumor agents based on the scaffold hybridization strategy. European Journal of Medicinal Chemistry. 2020,203,112601.

13.Xiao-Jing Shi, Yongjun Wei*, Boyang Ji*. Systems Biology of Gastric Cancer: Perspectives on the Omics-Based Diagnosis and Treatment. Frontiers in Molecular Biosciences. 2020, 7: 203. (IF 5.23)

14.Moges Dessale Asmamaw, Ying Liu, Yi-Chao Zheng, Xiao-Jing Shi*, Hong-Min Liu*. Skp2 in the ubiquitin-proteasome system: A comprehensive review. Medicinal Research Reviews. 2020; 1–30.

15.Yalei Miao, Yudian Qiu, Mengna Zhang, Ke Yan, Panke Zhang, Siyu Lu, Zhongyi Liu*, Xiaojing Shi*, Xubo Zhao*. Aqueous SelfAssembly of Block Copolymers to Form Manganese OxideBased Polymeric Vesicles for Tumor MicroenvironmentActivated Drug Delivery. Nano-Micro Letters. 2020, 12:124.

16.Liu Zhenzhen, Zhao Taoqian, Li Zhonghua, Sun Kai, Fu Yundong, Cheng Ting, Guo Jimin, Yu Bin*, Shi Xiaojing*, Liu Hongmin*, Discovery of [1,2,3]triazolo[4,5-d]pyrimidine derivatives as highly potent, selective, and cellularly active USP28 inhibitors. Acta Pharmaceutica Sinica B. 2020,10(8),1476-1479.

17.Wang Shuai^#, Zhao Lijie^#, Shi Xiaojing^#, Ding Lina^#, Yang Linlin, Wang Zhizheng, Shen Dandan, Tang Kai, Li Xiaojing, MAA Mamun, Li Huiju, Yu Bin*, Zheng Yi-Chao*, Wang Shaomeng*, Liu Hong-Min*; The development of highly potent, selective, and cellular active triazolo[1,5-a]pyrimidine-based inhibitors targeting the DCN1-UBC12 protein-protein interaction. Journal of Medicinal Chemistry. 2019, 62, 5: 2772-97.

18.Xiao-Jing Shi^#, Lina Ding^#, Wenjuan Zhou^#, Yage Ji, Junwei Wang, Huimin Wang, Yongcheng Ma, Guozhong Jiang, Kai Tang, Yu Ke*, Wen Zhao*, Hong-Min Liu*. Pro-apoptotic effects of JDA-202, a novel natural diterpenoid, on esophageal cancer through targeting peroxiredoxin I. Antioxidants& Redox Signaling. 2017, 10;27(2):73-92.